One of our key targets is BAX Inhibitor-1 (BI-1), a intracellular transmembrane protein.
Since first discovered over 20 years ago, BI-1 has generated growing interest from researchers recently, due to the essential role it plays in tumorigenesis and other diseases.
Target and Diseases
BI-1 is a highly conserved protein that exists in all eukaryotes, serving the key function of regulating cell stress.
It regulates endoplasmic reticulum stress (pro-apoptotic signaling), reactive oxygen species (ROS) production and breakdown, immunomodulation, and calcium homeostasis amongst other pathways.
However, creating drugs to target BI-1 has proven challenging due to the lack of ways to obtain the structure of BI-1, until MicroQuin's breakthrough.
What We Do
MicroQuin is the only company in the world that has been able to create targeted therapeutics to modulate of BI-1, having developed unchallenged level of IPs of the targets, through a decade of research, and the collaborations with our partners such as NASA/International Space Station.
In the case of oncology, MicroQuin uniquely treats cancer as a disease state, rather than target specific attributions for a particular person or cell type that could be limited to a small subset, may mutate, or may develop immunity, amongst other challenges.